BRAFTOVI vs TAXOTERE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. BRAFTOVI and TAXOTERE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BRAFTOVI	TAXOTERE
Rating	New	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	ENCORAFENIB	DOCETAXEL
Manufacturer	Array Biopharma Inc	Sanofi Aventis US
Dosage forms	Capsule	Injectable
Drug class	—	Microtubule Inhibitor
Boxed warning	None	Boxed warning
Treats	Melanoma	Breast Neoplasms, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms

braftovi taxotere

Rating

New

70/100

Pharmacy pays

—

Type

Active ingredient

ENCORAFENIB

DOCETAXEL

Manufacturer

Array Biopharma Inc

Sanofi Aventis US

Dosage forms

Capsule

Injectable

Drug class

—

Microtubule Inhibitor

Boxed warning

None

Boxed warning

Treats

Melanoma

Breast Neoplasms, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms

Frequently asked questions

What is the difference between Braftovi and Taxotere?

Braftovi contains Encorafenib, while Taxotere contains Docetaxel — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.